MX172918B - Composicion a base de l-3,4-dihidroxifenilalanina - Google Patents

Composicion a base de l-3,4-dihidroxifenilalanina

Info

Publication number
MX172918B
MX172918B MX007910A MX791087A MX172918B MX 172918 B MX172918 B MX 172918B MX 007910 A MX007910 A MX 007910A MX 791087 A MX791087 A MX 791087A MX 172918 B MX172918 B MX 172918B
Authority
MX
Mexico
Prior art keywords
weight during
dihydroxyphenylalanine
based composition
dopa
release
Prior art date
Application number
MX007910A
Other languages
English (en)
Inventor
Curt Henry Applegren
Eva Christina Eskilsson
Original Assignee
Asta Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma Ag filed Critical Asta Pharma Ag
Publication of MX172918B publication Critical patent/MX172918B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Fats And Perfumes (AREA)

Abstract

La presente invención se refiere a composición a base de L-3,4-dihidroxifenil-alanina (L-dopa) en particulas sólidas, adaptadas para ingestión oral, que consiste esencialmente de 75-85 por ciento por peso de L-dopa revestida con un laminado que consiste de una capa interior de 3.2-4.5 por ciento por peso de hidroxipropil metilcelulosa, y 1.2-2.4 por ciento por peso de etil celulosa, y una capa externa de 6.0-0.9 por ciento por peso de ftalato de hidroxipropilmetilcelulosa que tiene un pKa de 5.0, la cual composición en una prueba de liberación de acuerdo con las Normas de Farmacopea de E.U.A. (USP XXI, aparato 2,100 rpm) en un jugo gástrico artificial sin enzimas y que tiene un pH de hasta 1.2, libera cuando más 20 por ciento por peso de la L-dopa durante una hora y después de acuerdo con la misma norma de liberación en un amortiguador de fosfato que tiene un pH de 6.8 libera cuando menos 35 por ciento por peso de la L-dopa dentro de la primera hora y cuando menos 80 por ciento por peso dentro de las siguientes tres horas.
MX007910A 1986-08-26 1987-08-25 Composicion a base de l-3,4-dihidroxifenilalanina MX172918B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa

Publications (1)

Publication Number Publication Date
MX172918B true MX172918B (es) 1994-01-21

Family

ID=20365397

Family Applications (1)

Application Number Title Priority Date Filing Date
MX007910A MX172918B (es) 1986-08-26 1987-08-25 Composicion a base de l-3,4-dihidroxifenilalanina

Country Status (15)

Country Link
US (1) US4981695A (es)
EP (1) EP0260236B1 (es)
JP (1) JPH0662405B2 (es)
AT (1) ATE58292T1 (es)
CA (1) CA1298198C (es)
DD (1) DD286107A5 (es)
DE (1) DE3766200D1 (es)
DK (1) DK442287A (es)
ES (1) ES2036221T3 (es)
FI (1) FI86689C (es)
HU (1) HU197211B (es)
MX (1) MX172918B (es)
NO (1) NO176549C (es)
PT (1) PT85591B (es)
SE (1) SE460947B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007055A1 (en) * 1989-01-06 1990-07-06 Garth Boehm Theophylline dosage form
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6492420B2 (en) 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US7530461B2 (en) 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US6992107B1 (en) 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US5997831A (en) * 1996-07-12 1999-12-07 Engelhard Corporation Method of catalytically treating the atmosphere and heat exchange devices produced thereby
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
CA2455621C (en) * 2001-07-26 2010-11-16 Merck Patent Gesellschaft Mit Beschraenkter Haftung Use of (r/s)-(-/+) or (s)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane for the treatment of extrapyramidal movement disorders
EP1490073A4 (en) * 2002-03-21 2006-02-01 Martin C Hinz SEGMENT OPTIMIZATION TECHNOLOGY FOR THE SEROTONIN AND CATECHOLAMINE SYSTEM
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
AU2004285532A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Administration of levodopa and carbidopa
EP1697481A2 (en) * 2003-12-09 2006-09-06 Spherics, Inc. Bioadhesive polymers with catechol functionality
US20080311191A1 (en) * 2004-08-27 2008-12-18 Avinash Nangia Multi-Layer Tablets and Bioadhesive Dosage Forms
US20080299204A1 (en) * 2005-06-23 2008-12-04 Spherics, Inc. Dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
EP1988887A2 (en) * 2006-01-13 2008-11-12 University of South Carolina Method and composition for the treatment of parkinson's disease
US20100226855A1 (en) * 2006-03-02 2010-09-09 Spherics, Inc. Rate-Controlled Oral Dosage Formulations
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1116256A (fr) * 1954-12-09 1956-05-07 Stylographe à bille
DE1128461B (de) * 1959-01-15 1962-04-26 Fernseh Gmbh Einrichtung zum Schutz einer Fernsehaufnahmeroehre gegen Fehl-bedienung ihrer motorisch angetriebenen Lichtstromregeleinrichtung
FR2116256A1 (en) * 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
JPS5518694B2 (es) * 1973-04-02 1980-05-21
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
DE2513940A1 (de) * 1975-03-29 1976-10-14 Merck Patent Gmbh Pharmazeutische zubereitung
DE2655331A1 (de) * 1976-12-07 1978-06-08 Hoechst Ag Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
JPS5436645A (en) * 1977-08-29 1979-03-17 Omron Tateisi Electronics Co Temperature control system for boiler
CH627077A5 (en) * 1978-01-01 1981-12-31 Sankyo Co Pharmaceutical composition which foams in the intestine
CH649216A5 (de) * 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4446138A (en) * 1982-02-10 1984-05-01 Pack Howard M Method and composition for reducing weight
JPS59139317A (ja) * 1983-01-31 1984-08-10 Teisan Seiyaku Kk 持続性のニフエジピン製剤
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa

Also Published As

Publication number Publication date
ES2036221T3 (es) 1993-05-16
DE3766200D1 (de) 1990-12-20
HU197211B (en) 1989-03-28
EP0260236A1 (en) 1988-03-16
EP0260236B1 (en) 1990-11-14
JPH0662405B2 (ja) 1994-08-17
NO176549B (no) 1995-01-16
NO873589L (no) 1988-02-29
DD286107A5 (de) 1991-01-17
JPS63139128A (ja) 1988-06-10
FI873672A0 (fi) 1987-08-25
NO873589D0 (no) 1987-08-25
NO176549C (no) 1995-04-26
CA1298198C (en) 1992-03-31
DK442287A (da) 1988-02-27
FI86689C (fi) 1992-10-12
SE460947B (sv) 1989-12-11
SE8603582L (sv) 1988-02-27
ATE58292T1 (de) 1990-11-15
PT85591B (pt) 1990-05-31
PT85591A (en) 1987-09-01
DK442287D0 (da) 1987-08-25
US4981695A (en) 1991-01-01
FI86689B (fi) 1992-06-30
HUT44438A (en) 1988-03-28
FI873672A (fi) 1988-02-27
SE8603582D0 (sv) 1986-08-26

Similar Documents

Publication Publication Date Title
MX172918B (es) Composicion a base de l-3,4-dihidroxifenilalanina
KR880700668A (ko) 특정 생체조직 부위로의 전달을 위한 아미노산 킬레이트의 조성물
DK0732935T3 (da) Lyofiliserede stamcellefaktorformuleringer
SE8502950L (sv) Ny galenisk retardform
CA2015186A1 (en) Nutrient composition
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
DK0862634T4 (da) Farmaceutisk præparat mod papillomavirustumorer og -infektioner
DK0414007T3 (da) Hidtil ukendt arginindeiminase, dens fremstillingsmetode og et anti-cancermiddel indeholdende dette enzym som en effektiv ingrediens
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
SE8803583L (sv) Farmaceutisk komposition
DE3764235D1 (de) Ifosfamid-lyophilisat und verfahren zu dessen herstellung.
NO883520D0 (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
HK50094A (en) Skin detergent composition
SE8701077D0 (sv) Pharmaceutical composition
AU572689B2 (en) Pharmaceutical compositions of dezocine
ES2178639T3 (es) Solucion estable de aminoacidos altamente concentrada.
ES8608861A1 (es) Procedimiento para la preparacion de composiciones farmaceuticas hidrosolubles a base de sales de fosfomicina.
ES8609351A1 (es) Procedimiento para la preparacion de composiciones farmaceuticas hidrosolubles a base de sales del acido (-) cis-1, 2-epoxi-propilfosfonico.